Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in African‐American men

• Published in: BJU international 2014-12, Vol.114 (6b), p.E50-E55
• Main Authors: Donin, Nicholas M., Loeb, Stacy, Cooper, Phillip R., Roehl, Kimberly A., Baumann, Nikola A., Catalona, William J., Helfand, Brian T.
• Format: Article
• Language: English
• Subjects: African‐American; Aged; Black or African American - genetics; Delayed Diagnosis - prevention & control; Early Detection of Cancer; Endoscopic Ultrasound-Guided Fine Needle Aspiration - statistics & numerical data; genetic variants; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; prostate cancer; Prostate-Specific Antigen - blood; Prostate-Specific Antigen - genetics; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; PSA; single nucleotide polymorphism; Unnecessary Procedures; White People - genetics
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.12647

Objective To evaluate whether genetic correction using the genetic variants prostate‐specific antigen (PSA)‐single nucleotide polymorphisms (SNPs) could reduce potentially unnecessary and/or delayed biopsies in African‐American men. Subjects and Methods We compared the genotypes of four PSA‐SNPs between 964 Caucasian and 363 African‐American men without known prostate cancer (PCa). We adjusted the PSA values based on an individual's PSA‐SNP carrier status, and calculated the percentage of men that would meet commonly used PSA thresholds for biopsy (≥2.5 or ≥4.0 ng/mL) before and after genetic correction. Potentially unnecessary and delayed biopsies were defined as those men who were below and above the biopsy threshold after genetic correction, respectively. Results Overall, 349 (96.1%) and 354 (97.5%) African‐American men had measured PSA levels